There have been poor launch sales of the new inhalable insulin system. Can it rebound?
Regulators are requiring all multi-dose pens be labeled “For single patient use only”.
The FDA has approved Sanofi’s once-daily basal insulin, but will it compete with Sanofi’s own Lantus?
The insulin automatically stabilized high blood-sugar in mice with diabetes.
Microcapsules inserted beneath the skin of mice slowly released insulin after being exposed to micro-shockwaves.
We get a glimpse into the marketing strategy for Afrezza.
Learn why people with Type 1 diabetes need this long-acting insulin, and treatment options.
A diabetes educator discusses diluted insulin, which can help stave off blood sugar swings.
Why are some forms of insulin so expensive, and what happens if you can't afford the price?
A man with Type 1 diabetes was denied insulin in a holding cell for almost a day.
The latest Q&A from the mailbag of Integrated Diabetes Services.
The makers of Lantus oust their CEO partly over insulin sales. Will this lead to lower prices for basal insulin?
We explore this issue and the science behind obesity with noted science writer Gary Taubes.
The insulin pen is big in Japan, so why not here? It has a lot to do with cost.
Tired of paying high prices for Sanofi’s basal insulin? An alternative to Lantus has been blocked from the marketplace.
How a late-night idea saved the lives of thousands with diabetes and still inspires diabetes researchers today.
But will the FDA’s pulmonary concerns and Exubera’s track record keep this inhalable insulin from getting serious air in the marketplace.
Modern formulas of insulin have helped curb allergy reactions, but not eliminated them. Here’s what you need to know.
Elizabeth Rowley says we must speak up for those with diabetes around the world who can’t find or afford insulin and test strips.
We sometimes forget that insulin is a hormone that can promote weight gain in people with Type 1 diabetes.